Sandoz has announced significant progress in resolving long-standing U.S. litigation related to the generic medicines market, entering into settlement agreements covering the majority of its remaining legacy antitrust cases in the United States. The company stated that the agreements are intended to resolve historical legal disputes while allowing it to remain focused on its core business of expanding access to affordable medicines.
Under the agreements, Sandoz will pay approximately USD 478.5 million. The largest settlement involves 43 U.S. states and territories, under which its U.S. subsidiary will pay USD 400 million over seven years beginning in 2027, along with an additional approximately USD 50 million to states that had previously settled related claims. A separate USD 28.5 million settlement will resolve litigation brought by indirect reseller plaintiffs.
The lawsuits alleged anti-competitive practices in the U.S. generic medicines market, including claims related to pricing and competition. Sandoz emphasized that the settlements do not constitute an admission of wrongdoing, and the company continues to deny the allegations. The agreements are aimed at avoiding prolonged litigation and bringing greater certainty to the business.
Sandoz noted that these settlements resolve most of its remaining U.S. generic antitrust litigation, although certain claims from individual plaintiffs that opted out of class settlements remain pending. The company said it will continue to defend itself in any outstanding cases as appropriate.
The company also confirmed that the financial impact of the settlements has been appropriately reflected in its provisions and that the agreements will not affect its full-year 2026 financial guidance or its medium-term outlook.
Sandoz said resolving these legacy matters marks another important milestone as it continues to strengthen its position as a leading global manufacturer of generic and biosimilar medicines, with a strategic focus on expanding patient access to high-quality, affordable healthcare worldwide.
